INSPIRE NOTICE: Inspire Medical Systems, Inc. (INSP) Investors are Notified of Securities Fraud Class Action and to Contact BFA Law by January 5

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - A class action lawsuit has been filed against Inspire Medical Systems and certain senior executives, with investors encouraged to contact BFA Law by January 5, 2026, to lead the case [1][3]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and is pending in the U.S. District Court for the District of Minnesota [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, but failed to prepare clinicians and payors, leading to delays in adoption and weak demand due to excess inventory of older devices [5][6]. - On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, attributing this to undisclosed factors including incomplete training at implanting centers and poor demand [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].